Loading

Strengthening the Future of Biotech Investing

June 19, 2025
Super Session
Special Program
205ABC
Whether it is FDA, tariffs, interest rates or geopolitical uncertainty, the macro has been exerting significant pressure on the biotech industry. Will there be widespread consolidation in the number of companies, the number of investment funds and the investors that manage them, and consequently the number of deals? Is this good for the industry, for biomedical innovation, and ultimately for patients? It is clear that investors are rethinking the future of investing in biomedical innovation. Biotech might look very different in a few years. Our panel will examine which forces are having the greatest influence and what the biotechnology community can do to attract stronger investment.
Moderator
Steve Seedhouse, PhD
Biotech Research Analyst
Cantor Fitzgerald
Speakers
Andrew Lam, PharmD
Managing Director, Head of Biotech Private Equity
Ally Bridge Group
Michael Margolis, RPh, MBA
Senior Managing Director, Head of Healthcare Investment Banking
Oppenheimer & Co. Inc.
Rami Rahal, PhD
Partner
MPM BioImpact
Josh Resnick, MD, MBA
Partner
RA Capital Management
Cindy Xiong, PhD
Partner
Foresite Capital
Back to Session List

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS